NY A07920

Requires insurance carriers and health plans to cover at least one abuse-deterrent opioid analgesic drug product per opioid active ingredient on their formularies

Prohibits cost-sharing for abuse-deterrent opioids from exceeding the lowest cost-sharing level applied to equivalent non-abuse-deterrent opioids (brand name compared to brand name, generic to generic)

Bans insurers from increasing patient cost-sharing or creating disincentives for prescribers/dispensers to achieve compliance with coverage requirements

Prohibits prior authorization or utilization review requirements from forcing patients to first try non-abuse-deterrent opioids before accessing abuse-deterrent formulations

Takes effect 120 days after becoming law, applying to all policies issued, renewed, or modified after that date